You just read:

Combination of Checkpoint Inhibitors and Intezyne's Novel Cancer Resistance Pathway Inhibitor IT-139 Shows Enhanced Immune Efficacy

News provided by

Intezyne Technologies, Inc.

Apr 10, 2018, 08:40 ET